About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

A Dose Finding Study of VN-0200 | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 2NCT05547087

A Dose Finding Study of VN-0200

This study will assess the immunogenicity, safety and tolerability of VN-0200 after intramuscular injections in Japanese healthy elderly subjects.

Lead sponsor: Daiichi Sankyo•3 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Daiichi Sankyo

Age

60 - 80 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Japanese healthy elderly aged \>=60 and =\<80 years (at the time of informed consent).
•Subjects who can follow the compliance requirements during clinical trials, undergo medical examinations and tests specified by the protocol, and report symptoms, etc.

Exclusion Criteria

•Serious cardiovascular, respiratory, hepatic, renal, gastrointestinal, or neuropsychiatric disorders.
•Serious acute illness.
•Has been diagnosed with congenital or acquired immunodeficiency.
•Previous vaccination with an RSV vaccine (including the investigational drugs).
•Having a history of anaphylaxis or severe allergies due to medicines, or vaccination.
•Administration of gamma globulins, systemic immunosuppressants (including drugs for the treatment of autoimmune diseases), hematopoietics (excluding iron and vitamins), and corticosteroids (excluding topical preparations, inhalants, and small-dose short-term oral administration\*) or planned administration of them in the period starting 28 days prior to informed consent and ending 28 days after the second vaccination. \* \<14 days, 20 mg/day on a prednisolone basis.
•Planned or actual administration of other vaccine in the period starting 14 days prior to informed consent and ending 14 days after the second vaccination.

Related studies

RECRUITINGPhase 3

A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease

NCT07220109 · Respiratory Syncytial Virus Infections

RECRUITINGPhase 2

A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant

NCT07092865 · Respiratory Syncytial Virus Infections

Genotype and Disease Burden of RSV in Older Vietnamese Adults (RSV: Respiratory Syncytial Virus )

NCT07239583 · Respiratory Syncytial Virus Infection, Respiratory Syncytial Virus Infections

Active Not RecruitingPhase 3

Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above

NCT04732871 · Respiratory Syncytial Virus Infections

Active Not RecruitingPhase 3

An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study

NCT06534892 · Respiratory Syncytial Virus Infections

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: February 29, 2024Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment342

Start dateOct 2022

Last updatedFeb 29, 2024

Condition

Respiratory Syncytial Virus Infections

Locations shown

SOUSEIKAI PS Clinic

Hakata, Fukuoka

SOUSEIKAI Sumida Hopital

Sumida City, Tokyo

SOUSEIKAI Nishi-Kumamoto Hospital

Kumamoto

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 29, 2024Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions